Mirum Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: MIRM · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1759425

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Auditor Ratification

TL;DR

Mirum Pharmaceuticals will hold its 2024 Annual Meeting on June 5, 2024, to elect directors, ratify auditors, and vote on executive compensation.

AI Summary

Mirum Pharmaceuticals, Inc. (MIRM) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Annual Meeting scheduled for June 5, 2024, in a hybrid format (in-person and online). Purpose includes electing three Class II nominees for director until 2027. Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024. Advisory vote to approve named executive officer compensation. Advisory vote to determine the preferred frequency of executive compensation votes.

Why It Matters

For investors and stakeholders tracking Mirum Pharmaceuticals, Inc., this filing contains several important signals. Stockholders will vote on the election of directors, impacting the company's governance and strategic direction. The ratification of the independent auditor and advisory votes on executive compensation are key governance matters for shareholder oversight.

Risk Assessment

Risk Level: low — Mirum Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with no immediate financial or operational changes disclosed.

Analyst Insight

Stockholders should review the director nominees and executive compensation proposals before the June 5, 2024 meeting.

Key Numbers

Key Players & Entities

FAQ

When did Mirum Pharmaceuticals, Inc. file this DEF 14A?

Mirum Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Mirum Pharmaceuticals, Inc. (MIRM).

Where can I read the original DEF 14A filing from Mirum Pharmaceuticals, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Mirum Pharmaceuticals, Inc..

What are the key takeaways from Mirum Pharmaceuticals, Inc.'s DEF 14A?

Mirum Pharmaceuticals, Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Annual Meeting scheduled for June 5, 2024, in a hybrid format (in-person and online).. Purpose includes electing three Class II nominees for director until 2027.. Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024..

Is Mirum Pharmaceuticals, Inc. a risky investment based on this filing?

Based on this DEF 14A, Mirum Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting with no immediate financial or operational changes disclosed.

What should investors do after reading Mirum Pharmaceuticals, Inc.'s DEF 14A?

Stockholders should review the director nominees and executive compensation proposals before the June 5, 2024 meeting. The overall sentiment from this filing is neutral.

How does Mirum Pharmaceuticals, Inc. compare to its industry peers?

Mirum Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.

Are there regulatory concerns for Mirum Pharmaceuticals, Inc.?

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing the solicitation of proxies.

Industry Context

Mirum Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing the solicitation of proxies.

What Investors Should Do

  1. Review the proxy statement for details on director nominees.
  2. Understand the proposals regarding executive compensation and auditor ratification.
  3. Vote by the deadline to ensure participation in corporate governance.

Key Dates

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting, providing details on upcoming proposals and meeting logistics.

Filing Stats: 4,913 words · 20 min read · ~16 pages · Grade level 14.2 · Accepted 2024-04-23 16:20:09

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 8 PROPOSAL 1 ELECTION OF DIRECTORS 9 Class II Nominees for Election for a Three-year Term Expiring at the Company's 2027 Annual Meeting of Stockholders 10 Class III Directors Continuing in Office Until the Company's 2025 Annual Meeting of Stockholders 12 Class I Directors Continuing in Office Until the Company's 2026 Annual Meeting of Stockholders 14 INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE 16 Director Nomination Process and Qualifications 16 Nominations by Stockholders 16 Independence of the Board of Directors 16 Board Diversity 17 Board Leadership Structure 18 Role of the Board in Risk Oversight 18 Meetings of the Board of Directors 19 Information Regarding Committees of the Board of Directors 19 Audit Committee 20 Compensation Committee 21 Nominating and Corporate Governance Committee 22 Board ' s Oversight of Strategy 22 Stockholder Communications With the Board 23 Code of Conduct 23 Prohibition on Speculative Trading* 23 PROPOSAL 2 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 24 PROPOSAL 3 ADVISORY VOTE ON EXECUTIVE COMPENSATION 25 PROPOSAL 4 ADVISORY VOTE ON THE FREQUENCY OF SOLICITATION OF ADVISORY STOCKHOLDER APPROVAL OF EXECUTIVE COMPENSATION 26 EXECUTIVE OFFICERS 27

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 29

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 32 Summary Compensation Table 32 Annual Base Salary 32 Bonus Compensation 33 Pension Benefits 34 Nonqualified Deferred Compensation 34 Agreements with our Named Executive Officers 35 Outstanding Equity Awards at Fiscal Year End 36 Potential Payments Upon Termination or Change of Control 36 Employee Benefit Plans 37 Clawbacks 37 Equity Compensation Plan Information 38 2020 Inducement Plan 38 401(k) Plan 39 Limitations on Liability and Indemnification 39 ITEM (402)v PAY VERSUS PERFORMANCE 40 DIRECTOR COMPENSATION 43 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION 45 i TABLE OF CONTENTS Investors' Rights Agreement 45 Participation in August 2022 Follow-On Public Offering 45 Participation in April 2023 Convertible Notes Offering 45 Participation in August 2023 Private Placement 45 Indemnification Agreements 45 Policies and Procedures for Transactions with Related Persons 46 DELINQUENT SECTION 16(A) REPORTS 46 OTHER INFORMATION FOR STOCKHOLDERS 46 Stockholders Proposals for the 2025 Annual Meeting of Stockholders 46 Householding of Proxy Materials 47 OTHER MATTERS 48 ii TABLE OF CONTENTS MIRUM PHARMACEUTICALS, INC. 950 Tower Lane, Suite 1050 Foster City, California 94404 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 5, 2024 Proposals Page Board Recommendation Proposal 1 Elect the Board's three Class II nominees for director named herein to hold office until the Company's 2027 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal (" Director Election Proposal ") 9 For each of the Board's nominees for director Proposal 2 Ratify the selection by the Audit Committee of the Board of Directors of Ernst Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 (" A

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing